The Retinal Dopaminergic Circuit as a Biomarker for Huntington’s and Alzheimer’s Diseases
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125532 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pedro Blanco-Hernán und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Huntington Disease, Alzheimer Disease, Retina, Dopamine. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III (ISCIII), Spanish Ministerio de Ciencia e Innovación.
Themen: Demenz
Abstract (Originalsprache)
Retinal dysfunction is emerging as a potential early marker of neurodegenerative diseases. Within the retina, the dopaminergic circuit, comprising dopaminergic amacrine cells, dopamine synthesis and turnover, and dopamine receptor signalling, is essential for visual processing, particularly colour contrast perception. Disruption of this circuit may underline early retinal alterations observed in Huntington’s disease (HD) and Alzheimer’s disease (AD). In this study, we systematically analysed retinal dopaminergic dysfunction in murine models of HD (genetic origin) and AD (sporadic), across different disease stages. We assessed dopamine levels, turnover, tyrosine hydroxylase expression, D1 and D2 receptor gene expression, and neurotransmitter balance. HD mice showed early and marked alterations: reduced dopamine content, decreased tyrosine hydroxylase, increased turnover, and downregulation of D1 receptor expression—all preceding motor symptoms and detectable brain pathology. In contrast, AD mice showed only mild changes at later stages; however, clinical evidence suggests that similar dysfunction may occur earlier in human AD. These findings position retinal dopaminergic disruption as a potential early biomarker in HD and possibly in AD. While the current study relies on invasive techniques in animal models, it lays the groundwork for non-invasive retinal assessments, such as electroretinography or optical coherence tomography, as promising tools for early diagnosis and disease monitoring in neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
- Servicio de Neurobiología-Investigación, Hospital Ramón y Cajal, 28034 Madrid, Spain.
- Department of Systems Biology, Universidad de Alcalá (UAH), 28871 Alcalá de Henares, Spain.
ORCID-Profile: Pedro de la Villa
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Instituto de Salud Carlos III (ISCIII)
- Spanish Ministerio de Ciencia e Innovación
Zitieren
APA
Blanco-Hernán, P., Aguado, L., Asensio, M. J., Gómez-Soria, A., de la Villa, P., Casarejos, M. J., & Mansilla, A. (2025). The Retinal Dopaminergic Circuit as a Biomarker for Huntington’s and Alzheimer’s Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125532
Vancouver
Blanco-Hernán P, Aguado L, Asensio MJ, Gómez-Soria A, de la Villa P, Casarejos MJ, et al. The Retinal Dopaminergic Circuit as a Biomarker for Huntington’s and Alzheimer’s Diseases. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125532
BibTeX
@article{BlancoHernn2025,
author = {Blanco-Hernán, Pedro and Aguado, Lorena and Asensio, María José and Gómez-Soria, Ana and de la Villa, Pedro and Casarejos, María José and Mansilla, Alicia},
title = {The Retinal Dopaminergic Circuit as a Biomarker for Huntington’s and Alzheimer’s Diseases},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125532}
}
EUVIMED